• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Chattem

Chattem

  1. All
  2. Morningstar Articles
  3. Investing
  1. Active vs. Passive Investing: A Bottom Line

    Chattem's CHTT second-quarter results were in line with our expectations, so our fair value estimate for the shares remains unchanged. The firm is already reaping the benefits of the five brands it acquired from Johnson & Johnson JNJ in early January in the form of sales growth and improving ...

  2. Invest With These Exemplary Management Teams

    These great businesses are undervalued and run by CEOs that are looking out for the best interests of shareholders.

  3. Finding Moats in Big Pharma's Consumer Health Units

    We believe breakups could unlock value for big pharma shareholders.

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.